Close this search box.

AbSolutions Med, Inc. Granted FDA Breakthrough Device Designation for REBUILD™ Bioabsorbable Abdominal Wall Closure Device, Announces BioSpace

AbSolutions Med, Inc., a leading medical device company, has recently been granted the prestigious FDA Breakthrough Device Designation for its innovative product, the REBUILD™ Bioabsorbable Abdominal Wall Closure Device. This breakthrough designation is a significant milestone for the company and highlights the potential of this device to revolutionize abdominal wall closure procedures.

The REBUILD™ Bioabsorbable Abdominal Wall Closure Device is designed to address the challenges associated with traditional abdominal wall closure methods. It offers a unique solution that combines strength, flexibility, and bioabsorbability, providing surgeons and patients with a more efficient and effective alternative.

Abdominal wall closure is a critical step in various surgical procedures, including hernia repairs, cesarean sections, and other abdominal surgeries. Traditional methods often involve the use of non-absorbable sutures or mesh, which can lead to complications such as infection, chronic pain, and tissue damage. These complications can significantly impact patient recovery and overall outcomes.

The REBUILD™ device aims to overcome these challenges by utilizing a bioabsorbable material that gradually breaks down over time, eliminating the need for suture removal or long-term foreign body presence. This innovative approach not only reduces the risk of complications but also simplifies the post-operative care process for both patients and healthcare providers.

The FDA Breakthrough Device Designation is granted to medical devices that demonstrate the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. This designation expedites the development and review process, allowing AbSolutions Med, Inc. to work closely with the FDA to bring this groundbreaking device to market faster.

The recognition from the FDA further validates the potential impact of the REBUILD™ Bioabsorbable Abdominal Wall Closure Device in improving patient outcomes and revolutionizing surgical procedures. It also highlights the commitment of AbSolutions Med, Inc. to innovation and addressing unmet medical needs.

In addition to the FDA Breakthrough Device Designation, AbSolutions Med, Inc. has also announced its partnership with BioSpace, a leading online community and resource for life science professionals. This collaboration aims to raise awareness about the REBUILD™ device and its potential benefits among healthcare providers, surgeons, and patients.

Through this partnership, AbSolutions Med, Inc. and BioSpace will work together to disseminate information about the device, its clinical trials, and its anticipated availability. This collaboration will help ensure that healthcare professionals and patients are well-informed about this groundbreaking technology and can make informed decisions regarding their surgical procedures.

The FDA Breakthrough Device Designation for the REBUILD™ Bioabsorbable Abdominal Wall Closure Device marks a significant milestone for AbSolutions Med, Inc. and highlights the potential of this innovative device to transform abdominal wall closure procedures. With the support of BioSpace, the company aims to bring this breakthrough technology to market and improve patient outcomes in abdominal surgeries worldwide.